Antibodies to VLA-1

Details Antibodies to VLA-1 Antibodies to VLA-1

2011-03-22

2011-03-22

Haddad, Maher M (Department: 1644)

Drug, bio-affecting and body treating compositions

Immunoglobulin, antiserum, antibody, or antibody fragment,...

C424S133100, C424S144100

Reexamination Certificate

active

07910099

ABSTRACT:
Antibodies that specifically bind to VLA-1 integrin and methods of using these antibodies to treat immunological disorders in a subject. Also included are crystal structures of complexes formed by VLA-1 antibodies and their ligands, and VLA-1 antagonists and agonists identified by using the structure coordinates of these structures.

REFERENCES:
patent: 5391481 (1995-02-01), Chess et al.
patent: 5565332 (1996-10-01), Hoogenboom et al.
patent: 5648260 (1997-07-01), Winter et al.
patent: 5733743 (1998-03-01), Johnson et al.
patent: 5788966 (1998-08-01), Chess et al.
patent: 5789650 (1998-08-01), Lonberg et al.
patent: 5798230 (1998-08-01), Bornkamm et al.
patent: 5827690 (1998-10-01), Meade et al.
patent: 5855888 (1999-01-01), Nishida et al.
patent: 5859205 (1999-01-01), Adair et al.
patent: 6001961 (1999-12-01), Jonczyk et al.
patent: 6016159 (2000-01-01), Faris
patent: 6075181 (2000-06-01), Kucherlapati et al.
patent: 6127524 (2000-10-01), Casipit et al.
patent: 6150584 (2000-11-01), Kucherlapati et al.
patent: 6162963 (2000-12-01), Kucherlapati et al.
patent: 6180370 (2001-01-01), Queen et al.
patent: 6291650 (2001-09-01), Winter et al.
patent: 6300064 (2001-10-01), Knappik et al.
patent: 6303313 (2001-10-01), Wigler et al.
patent: 6307026 (2001-10-01), King et al.
patent: 6326403 (2001-12-01), Hölzemann et al.
patent: 6632927 (2003-10-01), Adair et al.
patent: 0 239 400 (1987-09-01), None
patent: 0 843 961 (1998-05-01), None
patent: 08-131185 (1996-05-01), None
patent: 08131185 (1996-05-01), None
patent: WO 90/07861 (1990-07-01), None
patent: WO 99/61040 (1999-12-01), None
patent: WO 99/61040 (1999-12-01), None
patent: WO 00/20459 (2000-04-01), None
patent: WO 00/72881 (2000-12-01), None
patent: WO 01/73444 (2001-10-01), None
patent: WO 01/96365 (2001-12-01), None
Padlan E.A., “Anatomy of the antibody molecule”, Mol Immunol., Feb. 1994; 31(3):169-217.
Panka et al., “Variable region framework differences results in decreased or increased affinity of variant anti-digoxin antibodies”, Proc Natl Acad Sci USA, May 1988; 85(9); 3080-4.
Portolano et al., “Lack of promiscuity in autoantigen-specific H and L chain combinations as revealed by human H and L chain “roulette””, J Immunol., Feb. 1, 1993; 150(3): 880-7.
E.T. Baldwin et al., “Cation Binding to the Integrin CD11b I Domain and Activation Model Assessment,”Structure,6:923-935 (1998).
R. Briesewitz et al., “Expression of Native and Truncated Forms of the Human Integrin α1Subunit,”J. Biol. Chem., 268:2989-2996 (1993).
P. Carter et al., “Humanization of an Anti-p185HER2Antibody for Human Cancer Therapy,”Proc. Natl. Acad. Sci. USA, 89:4285-4289 (1992).
C. Chothia et al., “Conformations of Immunoglobulin Hypervariable Regions,”Nature, 342:877-883 (1989).
M.S. Co et al., “Humanized Antibodies for Antiviral Therapy,”Proc. Nat. Acad. Sci. USA, 88:2869-2873 (1991).
A.L. Corbi et al., “The Human Leukocyte Adhesion Glycoprotein Mac-1 (Complement Receptor Type 3, CD11b) α Subunit,”J. Biol. Chem., 263:12403-12411 (1988).
A.L. Corbi at al., “cDNA Cloning and Complete Primary Structure of the α Subunit of a Leukocyte Adhesion Glycoprotein, P150,95,”EMBO J., 6:4023-4028 (1987).
D. Cosgrove, et al., “Integrin α1β1 and Transforming Growth Factor-β1 Play Distinct Roles in Alport Glomerular Pathogenesis and Serve as Dual Targets for Metabolic Therapy,”Am. J. Path., 157:1649-1659 (2000).
D.R. Davies and G.H. Cohen, “Interactions of Protein Antigens with Antibodies,”Proc. Natl. Acad. Sci. USA, 93:7-12 (1996).
A.R. de Fougerolles et al., “Global Expression Analysis of Extracellular Matrix-Integrin Interactions in Monocytes,”Immunity, 13:749-758 (2000).
C.P. Edwards et al., “Identification of Amino Acids in the CD11a I-domain Important for Binding of the Leukocyte Function-associated Antigen-1 (LFA-1) to Intercellular Adhesion Molecule-1 (ICAM-1)”,J. Biol. Chem., 270, 12635-12640 (1995).
C. Eigenbrot et al., “X-ray Structures of the Antigen-binding Domains from Three Variants of Humanized anti-p185HER2Antibody 4D5 and Comparison with Molecular Modeling,”J. Mol. Biol., 229:969-995 (1993).
J. Emsley et al., “Structural Basis of Collagen Recognition by Integrin α2β1,”Cell,.100:47-56 (2000).
J. Emsley et al., “Crystal Structure of the I Domain from Integrin α2β1,”J. Biol. Chem., 272:28512-28517 (1997).
J. Foote and G. Winter, “Antibody Framework Residues Affecting the Conformation of the Hypervariable Loops,”J. Mol. Biol., 224:487-499 (1992).
A.A. Gaspari and S.I. Katz, “Contact Hypersensitivity,”Current Protocols in Immunology. J.E. Coligan, A.M. Kruisbeek, D.H. Margulies, E.M. Shevach, and W. Strober, editors. John Wiley & Sons, New York. Section 4.2.1-4.2.5 (1991).
P.J. Gotwals et al., “Divalent Cations Stabilize the α1β1 Integrin I Domain,”Biochemistry, 38:8280-8288 (1999).
P.J. Gotwals et al., “The α1β1 Integrin Is Expressed during Neointima Formation in Rat Arteries and Mediates Collagen Matrix Reorganization,”J. Clin. Invest., 97:2469-2477 (1996).
M.H. Grayson et al., αdβ2 Integrin Is Expressed on Human Eosinophils and Functions as an Alternative Ligand for Vascular Cell Adhesion Molecule 1 (VCAM-1),J. Exp. Med., 188:2187-2191 (1988).
L.L. Green et al., “Antigen-specific Human Monoclonal Antibodies From Mice Engineered With Human Ig Heavy and Light Chain YACs,”Nature Genetics, 7:13-21 (1994).
M.E, Hemler et al., “Very Late Activation Antigens on Rheumatoid Synovial Fluid T Lymphocytes: Association with Stages of T Cell Activation,”J. Clin. Invest., 78:696-702 (1986).
M.E. Hemler et al., “VLA-1: A T Cell Surface Antigen which Defines a Novel Late Stage of Human T Cell Activation,”Eur. J. Immunol., 15:502-508 (1985).
C. Huang and B.D. Stollar, “A Majority of Ig H Chain cDNA of Normal Human Adult Blood Lymphocytes Resembles cDNA for Fetal Ig and Natural Autoantibodies,”J. Immunol., 151:5290-5300 (1993).
B. Hurtrel at al., “Different Time Course Patterns of Local Expression of Delayed-Type Hypersensitivity to Sheep Red Blood Cells in Mice,”Cell. Immunol., 142:252-263 (1992).
J.R. Huth et al., “NMR and Mutagenesis Evidence for an I Domain Allosteric Site that Regulates Lymphocyte Function-Associated Antigen 1 Ligand Binding,”Proc. Natl. Acad. Sci. U.S.A., 97:5231-5236 (2000).
M.J. Ignatius et al., “Molecular Cloning of the Rat Integrin α1-Subunit: A Receptor for Laminin and Collagen,”J. Cell Biol., 111, 709-720 (1990).
S. Jones and J.M. Thornton, “Principles of Protein-Protein Interactions,”Proc. Natl. Acad. Sci. USA, 93:13-20 (1996).
P.T. Jones et al., “Replacing the Complementarity-Determining Regions in a Human Antibody with Those from a Mouse,”Nature, 321:522-525 (1986).
K. Kakimoto et al., “The Effect of Anti-adhesion Molecule Antibody on the Development of Collagen-Induced Arthritis,”Cell. Immunol., 142:326-337 (1992).
T. Kamata et al., “Critical Threonine and Aspartic Acid Residues within the I Domains of β2 Integrins for Interactions with Intercellular Adhesion Molecule 1 (ICAM-1) and C3bi,”J. Biol. Chem., 270:12531-12535 (1995).
P.J. Keely et al., “Alteration of Collagen-Dependent Adhesion, Motility, and Morphogenesis by the Expression of Antisense α2Integrin mRNA in Mammary Cells,”J. Cell Sci., 108:595-607 (1995).
A. Kern, et al., “The Role of the I Domain in Ligand Binding of the Human Integrin α1β1,”J. Biol. Chem., 269:22811-22816 (1994).
T. Kinashi and T.A. Springer, “Adhesion Molecules in Hematopoietic Cells,”Blood Cells, 20:25-44 (1994).
S.L. King, at al., “Echovirus 1 Interaction with the Human Very La

Affiliated with

Also associated with

Rating

Antibodies to VLA-1 does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Antibodies to VLA-1, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibodies to VLA-1 will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2663540